The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%. With markets...read more
Accounting for 100% of the four IPOs so far this year, biotechs appeared to be the one sector able to generate demand from public investors. But demand is weaker than...read more
Proteostasis Therapeutics, which is developing a protein modulator to treat cystic fibrosis, raised $50 million by offering 6.3 million shares at $8, below the range of $12 to $14. Proteostasis Therapeutics plans to list on the Nasdaq under the symbol PTI....read more
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
US IPO Weekly Recap: IPO market largely closed; two biotechs go public and break
The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%. With markets...read more
Biotechs lean heavily on insider buying to complete quasi-IPOs
Accounting for 100% of the four IPOs so far this year, biotechs appeared to be the one sector able to generate demand from public investors. But demand is weaker than...read more
Proteostasis Therapeutics prices IPO at $8, below the range
Proteostasis Therapeutics, which is developing a protein modulator to treat cystic fibrosis, raised $50 million by offering 6.3 million shares at $8, below the range of $12 to $14. Proteostasis Therapeutics plans to list on the Nasdaq under the symbol PTI....read more